Stephen Gordon sold $2.8M of TMDX
Chief Financial Officer at TransMedics Group, Inc.. 20,000 shares at an average of $141.40, traded May 29, 2024, filed May 31, 2024.
Score components
- +22RoleCFO
- +25Trade size$2.8M at market
- +20Share of holdings soldSold 86% of holdings
- +15Cluster6 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +10.4%, 3m +23.2%, 6m -36.4%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-24-067358, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 29, 2024 | SOpen-market sale Common Stock | -2,000 | $141.27 | $283k | 21,299 | May 31, 2024 |
| May 29, 2024 | MOption exercise Common Stock | +2,000 | $16.14 | $32k | 23,299 | May 31, 2024 |
| May 29, 2024 | MOption exercise Common Stock | +5,000 | $38.46 | $192k | 28,299 | May 31, 2024 |
| May 29, 2024 | MOption exercise Common Stock | +5,000 | $13.28 | $66k | 33,299 | May 31, 2024 |
| May 29, 2024 | MOption exercise Common Stock | +1,000 | $83.14 | $83k | 34,299 | May 31, 2024 |
| May 29, 2024 | MOption exercise Common Stock | +5,000 | $66.10 | $331k | 39,299 | May 31, 2024 |
| May 29, 2024 | SOpen-market sale Common Stock | -9,345 | $141.06 | $1.3M | 29,954 | May 31, 2024 |
| May 29, 2024 | SOpen-market sale Common Stock | -8,655 | $141.80 | $1.2M | 21,299 | May 31, 2024 |
| May 29, 2024 | MOption exercise Stock Option (Right to Buy)derivative | -2,000 | $0.00 | $0 | 84 | May 31, 2024 |
| May 29, 2024 | MOption exercise Stock Option (Right to Buy)derivative | -5,000 | $0.00 | $0 | 17,477 | May 31, 2024 |
| May 29, 2024 | MOption exercise Stock Option (Right to Buy)derivative | -5,000 | $0.00 | $0 | 23,167 | May 31, 2024 |
| May 29, 2024 | MOption exercise Stock Option (Right to Buy)derivative | -1,000 | $0.00 | $0 | 17,690 | May 31, 2024 |
| May 29, 2024 | MOption exercise Stock Option (Right to Buy)derivative | -5,000 | $0.00 | $0 | 15,022 | May 31, 2024 |
Related signals
Other insiders at TransMedics Group, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 36Weak | TMDXbuy TransMedics Group, Inc. | David Weill director | $109k 1,336 shares | +9% | |
| 31Weak | TMDXsell TransMedics Group, Inc. | Thomas James Gunderson director | $722k 9,624 shares | -37% | |
| 52Moderate | TransMedics Group, Inc. | Stephanie Lovell director | $178k 1,193 shares | -29% | |
| 38Weak | TransMedics Group, Inc. | David Weill director | $524k 3,571 shares | -23% | |
| 46Moderate | TransMedics Group, Inc. | Nicholas Corcoran See remarks | $413k 2,966 shares | -9% | |
| 67Notable | TransMedics Group, Inc. | Gerardo Hernandez Chief Financial Officer | $1.1M 7,611 shares | -51% | |
| 40Moderate | TransMedics Group, Inc. | Anil P. Ranganath See remarks | $120k 864 shares | -6% | |
| 48Moderate | TransMedics Group, Inc. | Gerardo Hernandez Chief Financial Officer | $128k 920 shares | -6% | |
| 46Moderate | TransMedics Group, Inc. | David Weill director | $693k 5,000 shares | -29% | |
| 37Weak | TransMedics Group, Inc. | Anil P. Ranganath See remarks | $436k 3,000 shares | -18% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.